Barrington analyst Michael Petusky raised the firm’s price target on Orthofix (OFIX) to $18 from $17 and keeps an Outperform rating on the shares. The company reported strong Q3 results and upped the low-end of its fiscal 2025 EBITDA outlook, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OFIX: